Recombinant Human CD19 cell lysate

• Cat.No.: CD19-2005HCL
• Product Overview: Human CD19 / Leu-12 derived in Human Cells. The whole cell lysate is provided in 1X Sample Buffer.Browse all transfected cell lysate positive controls

Specification

• Source: Human cells
• Species: Human
• Preparation method: Transfected cells were cultured for 48hrs before collection. The cells were lysed in modified RIPA buffer with cocktail of protease inhibitors. Cell debris was removed by centrifugation and then centrifuged to clarify the lysate. The cell lysate was boiled for 5 minutes in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% b-mercaptoethanol, and lyophilized.
• Lysis buffer: Modified RIPA Lysis Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF
• Quality control Testing: 12.5% SDS-PAGE Stained with Coomassie Blue
• Recommended Usage: 1. Centrifuge the tube for a few seconds and ensure the pellet at the bottom of the tube.2. Re-dissolve the pellet using 200μL pure water and boiled for 2-5 min.3. Store it at -80°C. Recommend to aliquot the cell lysate into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.Notes:The lysate is ready to load on SDS-PAGE for Western blot application. If dissociating conditions are required, add reducing agent prior to heating.
• Stability: Samples are stable for up to twelve months from date of receipt at -80°C
• Storage Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF
• Storage Instruction: Lysate samples are stable for 12 months from date of receipt when stored at -80°C. Avoid repeated freeze-thaw cycles. Prior to SDS-PAGE fractionation, boil the lysate for 5 minutes.
• Tag: Non

Gene Information

• Gene Name: CD19 CD19 molecule [ Homo sapiens ]
• Official Symbol: CD19
• Synonyms: CD19; CD19 molecule; CD19 antigen; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4; B4; CVID3; MGC12802
• Gene ID: 930
• mRNA Refseq: NM_001178098
• Protein Refseq: NP_001171569
• MIM: 107265
• UniProt ID: P15391
• Chromosome Location: 16p11.2
• Pathway: Adaptive Immune System, organism-specific biosystem; Antigen Activates B Cell Receptor Leading to Generation of Second Messengers, organism-specific biosystem; B Cell Receptor Signaling Pathway, organism-specific biosystem; B cell receptor signaling pathway, organism-specific biosystem; B cell receptor signaling pathway, conserved biosystem; BCR signaling pathway, organism-specific biosystem; Hematopoietic cell lineage, organism-specific biosystem
• Function: receptor signaling protein activity

Reviews

01/02/2023

The manufacturer of CD19 protein has consistently provided outstanding technical support that has surpassed my expectations.

08/18/2022

This protein demonstrates remarkable purity, stability, and specificity, ensuring utmost accuracy and reproducibility in my research endeavors.

06/29/2016

Their dedication to customer satisfaction has been instrumental in overcoming obstacles and achieving successful results in my experiments.

Q&As

How does CAR-T cell therapy work to combat CD19-expressing cancers?

CAR-T cells are engineered to express a receptor that recognizes CD19 on the surface of cancerous B cells. When they encounter these cells, they destroy them.

Are there any diseases associated with CD19 dysfunction?

CD19 deficiencies can lead to primary immunodeficiencies, making individuals more susceptible to infections.

What are the potential side effects of CAR-T cell therapy targeting CD19?

Side effects may include cytokine release syndrome (CRS), neurologic toxicity, and long-term B-cell aplasia.

What are some CD19-expressing malignancies that CAR-T cell therapy can target?

CAR-T cell therapy is used to treat B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma.

How effective is CAR-T cell therapy in treating CD19-expressing cancers?

CAR-T cell therapy has shown remarkable effectiveness in inducing remissions in patients with CD19-positive malignancies, particularly in those who have relapsed or failed conventional treatments.